Alpha Tau to Present at the Jefferies Global Healthcare Conference
Alpha Tau Medical, a leader in alpha-radiation cancer therapy, announced its participation in the Jefferies Global Healthcare Conference on June 5, 2024. Their CFO, Raphi Levy, will present a corporate overview and update at the event scheduled from 1:30 to 1:55 PM EST in New York. Levy will also be available for one-on-one meetings with investors during the conference. Attendees are encouraged to contact their Jefferies representative to schedule a session.
- Alpha Tau's participation in a high-profile event like the Jefferies Global Healthcare Conference enhances its visibility among investors.
- The presentation by CFO Raphi Levy provides an opportunity to showcase the company's innovative Alpha DaRT™ technology.
- Availability for one-on-one meetings demonstrates Alpha Tau's commitment to engaging with investors and addressing their inquiries.
- The press release lacks specific financial updates or new clinical data, which might be expected by investors.
- No mention of recent achievements or milestones that could positively impact the stock price.
- The announcement is to an event participation without detailed insights into the company's strategic direction or financial health.
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Global Healthcare Conference on June 5th, 2024.
| Event: | Jefferies Global Healthcare Conference |
| Date: | June 5th, 2024 |
| Time: | 1:30-1:55 PM EST |
| Location: | New York, NY |
Mr. Levy will also be available for 1x1 investor meetings at the conference. Please reach out to your Jefferies representative to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact: IR@alphatau.com
FAQ
What event will Alpha Tau Medical participate in on June 5, 2024?
Who will represent Alpha Tau Medical at the Jefferies Global Healthcare Conference?
What time is Alpha Tau Medical's presentation at the Jefferies Global Healthcare Conference?
Where is the Jefferies Global Healthcare Conference taking place?
Will Alpha Tau Medical's CFO be available for investor meetings at the Jefferies Global Healthcare Conference?
What is Alpha Tau Medical's stock symbol?
